Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b
Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b
复制标题
使用干扰素 β-1b 治疗的原发进展型多发性硬化症患者痉挛加剧
DOI：
10.1212/wnl.51.6.1720
复制
发表时间：
1998
期刊：
影响因子：
9.9
通讯作者：
Fred D. Lublin
中科院分区：
文献类型：
--
作者：
A. Frese;Florian Bethke;P. Lüdemann;Florian Stögbauer;P. Bramanti;E. Sessa;C. Rifici;G. D'Aleo;D. Floridia;P. D. Bella;Fred D. Lublin
痉挛是MS的致残症状，在干扰素β-1b （IFNβ-1b）治疗期间增强。19例原发性进展性MS患者接受IFNβ-1b治疗；另外19名患者没有接受这种治疗。在接受IFNβ-1b治疗的19例患者中，有13例痉挛增加，需要增加抗痉挛药物的剂量。这一观察结果表明，在干扰素广泛应用于原发性进展性多发性硬化症患者之前，还需要进一步的研究。
Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFNβ-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNβ-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.